Roche and reMYND's DDD : strategic alliance to develop first-in-class disease-modifying treatments for Alzheimer's and Parkinson's disease

07-09-2010 - Roche (SIX: RO, ROG; OTCQX: RHHBY) and reMYND announced that they have entered into an agreement to develop novel therapeutics that could slow down neurodegeneration in Parkinson’s and Alzheimer’s patients by inhibiting α-synuclein and tau toxicity.

The collaboration will focus on two of reMYND’s pre-clinical small molecule programmes targeting α-synuclein and tau related pathologies in appropriate model systems as well as potential back-up classes. Roche and reMYND will form joint teams to progress the programmes towards clinical studies. Roche will provide input into chemistry, lead-optimisation and pre-clinical development, while reMYND will continue to conduct non-clinical pharmacology studies and further elucidate the underlying molecular mechanisms. Roche will be responsible for all clinical development and worldwide commercialisation.

reMYND’s compounds are unique because they inhibit α-synuclein neurotoxicity in Parkinson's disease and tau neurotoxicity in Alzheimer's disease. As such they are considered disease modifying, whilst most currently available treatments only treat the symptoms of the disease... reMYND's Press Release -

Ablynx and reMYND settle dispute amicably

2 June 2010 – Ablynx NV [Euronext Brussels: ABLX] and reMYND NV announced that they have reached a settlement concerning a dispute relating to a collaboration agreement to discover and commercialize new Nanobodies® which Ablynx and reMYND entered into in 2003. In 2007, Ablynx was notified by reMYND that a difference of interpretation existed in respect of Ablynx's contractual obligation to reMYND under the 2003 agreement.

Under this agreement, Ablynx had the obligation to pay reMYND 50% of any income received if certain Nanobodies from the above collaboration were licensed to a third party for development and commercialization. Ablynx has a collaboration with Boehringer Ingelheim in the area of Alzheimer’s disease with a potential deal value of $265 million plus royalties, under which, at this time, it believes, in contrast to reMYND, that no license to develop or commercialize any of the aforementioned Nanobodies has been granted... [PDF] reMYND's Press Release - Ablynx's newsroom -